updated 4/1/2011 8:46:26 AM ET 2011-04-01T12:46:26

WEST LAFAYETTE, Ind., April 1, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that the company has been added to the Russell 2000® Index, as part of Russell's quarterly IPO additions that took place on March 31, 2011, following the close of the market.

The Russell 2000® Index, a subset of the Russell 3000® Index, measures the performance of the small-cap segment of U.S. equities. Membership in the Russell 2000 also means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

About Russell Indexes

The Russell family of U.S. indexes is designed to be a comprehensive representation of the investable U.S. equity market and is reconstituted annually mid-year. Russell's U.S. indexes capture the 4,000 largest U.S. stocks, ranking them by total market capitalization. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets are benchmarked to the Russell indexes as of December 31, 2009.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

CONTACT: Vickey Buskirk
         Endocyte Inc.
         (765) 807-0617

         Stephanie Ascher
         Stern Investor Relations, Inc.
         (212) 362-1200

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.97%
$30K home equity loan FICO 5.23%
$75K home equity loan FICO 4.67%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.28%
13.21%
Cash Back Cards 17.74%
17.70%
Rewards Cards 17.01%
16.96%
Source: Bankrate.com